AstraZeneca announced positive results from the company’s Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
With increased access to insurance under the Affordable Care Act (also known as Obamacare), fewer uninsured patients have been hospitalized for serious heart conditions, a U.S. study suggests.
Bayer and Johnson & Johnson’s campaign to widen the patient group for the companies’ heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.
Pfizer Inc. announced that tafamidis received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the treatment of patients with transthyretin cardiomyopathy, which is a rare, fatal and underdiagnosed condition associated with progressive heart failure.
A Novartis executive said the Swiss company’s heart failure medicine Entresto could be used more widely in the future.
Eiger BioPharmaceuticals Inc. will stop development of a drug to treat pulmonary arterial hypertension after it failed in a mid-stage study.
People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.
BioSpace present its NextGen Bio “Class of 2018,” a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Canada’s Aeterna Zentaris Inc. said the U.S. FDA approved its oral test to diagnose adult growth hormone deficiency.
Amgen’s PSCK9 inhibitor Repatha continues to impress as a treatment for patients with peripheral artery disease (PAD) and a history of heart attacks. New data shows Repatha hit its primary endpoints and significantly reduced first-time cardiovascular events by 27 percent in PAD patients.